|
I.S. Vladimirova
Psoriasis, metabolic syndrome and COVID-19: a case report
|
№14 / 2022
|
|
R.A. Bontsevich, Ya.R. Vovk, V.A. Vinyukov, D.G. Dubonosova
Preferences of Belgorod primary care phycisians in the treatment of a new coronavirus infection
|
№10 / 2022
|
|
O.A. Bashkina, I.V. Vyazovaya, D.F. Sergienko
Pediatric inflammatory multisystem syndrome associated with COVID-19: a clinical case
|
№9 / 2022
|
|
A.A. Turovskaya, E.M. Kostina, E.A. Orlova, E.Yu. Trushina, G.M. Grishanovich, O.G. Sidorova, E.V. Avdoshina
Features of the clinical course of a new coronavirus infection in children
|
№9 / 2022
|
|
A.A. Astapovsky, V.N. Drozdov, E.V. Shikh, N.B. Lazareva, G.G. Melkonyan, A.A. Meshcheryakov, E.V. Tsepkova
Proadrenomedullin levels and clinical features of SARS-CoV-2 coronavirus infection: a prospective clinical study
|
№5 / 2022
|
|
N.V. Izmozherova, A.A. Popov, I.P. Antropova, L.I. Kadnikov, Ya.V. Livshits, A.D. Kushtyeva, A.A. Nikonova, V.M. Bakhtin, M.A. Shambatov
Exogenous glucocorticoids and the platelet component of the hemostasis system in COVID-19
|
№5 / 2022
|
|
I.B. Zhurtova, M.A. Elgarova, A.M. Gubachikova, M.R. Kurashinova
Manifestation of primary adrenal insufficiency in a child against the background of a novel coronovirus infection COVID-19: a clinical case
|
№1 / 2022
|
|
A.I. Tarzimanova, E.E. Bykova
Antiarrhythmic therapy for atrial fibrillation in patients with the novel SARS-CoV-2 coronavirus infection: how to make the right choice?
|
№13 / 2021
|
|
V.M. Tsvetov (1), I.S. Burashnikova (2), D.A. Sychev (3)
Possibility and prospects for the use of recombinant neutralizing monoclonal antibodies (bamlanivimab+etesevimab, sotrovimab) in patients with COVID-19
|
№12 / 2021
|
|
I.V. Kosheleva (1, 3), O.A. Bitkina (2), L.I. Shadyzheva (1), O.V. Andriyakhina (3), A.Yu. Nikolaeva (2), M.N. Fyrnina (2), M.A. Deryavaya (2), K.S. Pershina (2), D.S. Zueva (2), A.A. Tsyganova (2)
On the dermatological aspects of the novel coronavirus infection (COVID-19)
|
№8 / 2021
|
|
I.S. Burashnikova
The rationale for the combined use of genetically engineered biological drugs in patients with COVID-19
|
№8 / 2021
|
|
I.S. Burashnikova
The rationale for re-administration of genetically engineered biological drugs in patients with COVID-19
|
№8 / 2021
|
Русский
